|
시장보고서
상품코드
2091845
신경 영양성 각막염 치료 시장 규모, 점유율 및 성장 분석 : 치료법별, 질환의 진행 단계별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Neurotrophic Keratitis Treatment Market Size, Share, and Growth Analysis, By Treatment Type, By Disease Stage, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 신경 영양성 각막염 치료 시장 규모는 2024년에 46억 4,000만 달러로 평가되며, 2025년 50억 2,000만 달러에서 2033년까지 93억 6,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 8.1%로 성장할 것으로 전망되고 있습니다.
신경영양성 각막염 치료 시장은 안과 치료 분야에서 성장세를 보이고 있습니다. 그 주요 원인은 당뇨병, 굴절 교정 수술, 바이러스 감염증 등의 질환에 따른 각막 감각 상실의 발생률이 증가하고 있기 때문입니다. 이 시력을 위협하는 질환은 상피의 치유를 방해하므로 신경 기능을 회복시키고 재생을 촉진하는 치료법에 대한 수요가 높아지고 있습니다. 윤활유나 밴드형 렌즈에 중점을 두었던 기존의 치료 방식은, 재조합 인간 신경성장인자인 ‘세네게르민’과 같은 혁신적인 솔루션으로 점차 전환되고 있습니다. 규제 측면에서의 인센티브 강화와 보험 환급 제도 개혁은 진입 장벽을 낮추고 생물제제에 대한 투자를 촉진함으로써 시장 성장을 지원하는 중요한 동향이 되고 있습니다. 각 보험사들이 각막 천공 예방을 통한 비용 절감 효과를 인식함에 따라 효과적인 치료법의 보험 적용 범위를 확대하고 있으며, 이에 따라 제약사들은 주요 시장에서 다양한 제품 파이프라인 개발을 추진하고 있습니다.
전 세계 신경영양성 각막염 치료 시장의 성장 요인
신경영양성 각막염의 증상과 치료 옵션에 대한 임상의들의 인식이 높아지고 있는 것이 시장에 큰 영향을 미치고 있으며, 이는 보다 신속한 진단과 전문 의료 기관으로의 의뢰로 이어지고 있습니다. 이러한 인식의 확산은 혁신적인 치료법의 도입을 촉진할 뿐만 아니라, 치료의 혜택을 받을 수 있는 환자의 범위를 넓혀, 결과적으로 의사들이 새로운 치료법을 권장하는 데 있으며, 자신감을 높여주고 있습니다. 그 결과, 승인된 제품에 대한 수요가 증가하고 있으며, 제조사들은 교육 활동과 시장 홍보에 주력하고 있습니다. 이러한 임상 현장에 대한 지속적인 참여는 전 세계 다양한 의료 환경에서 환자의 접근성 개선과 치료 성과 향상을 촉진하며, 신경영양성 각막염 치료 시장의 전반적인 성장을 이끌고 있습니다.
전 세계 신경영양성 각막염 치료 시장의 제약 요인
신경영양성 각막염의 새로운 치료법 개발 및 제조에는 막대한 비용이 소요되므로 소매 가격이 급등하고 있으며, 많은 의료보험 제도에서 해당 비용의 보상에 어려움을 겪고 있습니다. 이러한 큰 경제적 장벽은, 특히 보험 선택지가 제한적이거나 공공 자금이 부족한 지역에서 환자들의 의료 서비스 이용을 제한하고 있습니다. 그 결과, 의료 서비스 제공자는 고가의 치료법을 권장하는 것을 주저하고, 대신 비용이 저렴한 대체요법이나 지지요법을 선택할 가능성이 있습니다. 이러한 재정적 부담은 시장 수요를 감소시키고, 치료법의 광범위한 보급을 저해하며, 혁신적인 치료법의 적시 도입을 방해하여, 궁극적으로는 전 세계 안과 시장 전체의 성장을 저해할 우려가 있습니다.
세계 신경영양성 각막염 치료 시장의 동향
전 세계 신경영양성 각막염 치료 시장은 첨단 영상 진단, 바이오마커 프로파일링, 인공지능(AI) 분석을 결합한 통합 진단 플랫폼의 등장으로 인해 인상적인 성장을 달성하고 있습니다. 이러한 혁신적인 융합을 통해 신경영양성 각막염의 진단 및 모니터링에 대한 임상 역량이 향상되어, 각막 신경 밀도와 눈물막의 동태를 보다 정확하게 평가할 수 있게 됩니다. 조기 개입과 환자 개개인에 맞춘 치료 옵션을 가능하게 함으로써, 이러한 플랫폼은 환자의 치료 순응도를 높이고 침습적 시술의 필요성을 줄여줍니다. 또한 이러한 추세는 안과 의사와 기술 제공업체 간의 협력을 촉진하고, 진단 기기 제조업체에 새로운 수익 기회를 가져다주는 동시에 시장의 성장세를 더욱 강화하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 신경 영양성 각막염 치료 시장 규모 : 치료 유형별
세계의 신경 영양성 각막염 치료 시장 규모 : 질환 스테이지별
세계의 신경 영양성 각막염 치료 시장 규모 : 투여 경로별
세계의 신경 영양성 각막염 치료 시장 규모 : 최종사용자별
세계의 신경 영양성 각막염 치료 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.07.22Global Neurotrophic Keratitis Treatment Market size was valued at USD 4.64 Billion in 2024 and is poised to grow from USD 5.02 Billion in 2025 to USD 9.36 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).
The neurotrophic keratitis treatment market is gaining traction within the ophthalmic therapeutics arena, primarily due to the increasing incidence of corneal sensory loss associated with conditions like diabetes, refractive surgery, and viral infections. This vision-threatening condition hampers epithelial healing, driving the need for therapies that restore nerve functionality and support regeneration. Traditional management approaches focused on lubricants and bandage lenses are shifting towards innovative solutions, such as cenegermin, a recombinant human nerve growth factor. Enhanced regulatory incentives and reimbursement reforms are pivotal trends bolstering market growth by lowering entry barriers and encouraging investment in biologics. As insurers acknowledge the cost savings from preventing corneal perforation, they broaden coverage for effective treatments, prompting pharmaceutical companies to develop diverse product pipelines in key markets.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurotrophic Keratitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Neurotrophic Keratitis Treatment Market Segments Analysis
Global neurotrophic keratitis treatment market is segmented by treatment type, disease stage, route of administration, end user and region. Based on treatment type, the market is segmented into recombinant human nerve growth factor (rhNGF) eye drops, topical antibiotics, amniotic membrane transplantation, keratoplasty, tarsorrhaphy and therapeutic contact lenses. Based on disease stage, the market is segmented into stage I, stage II and stage III. Based on route of administration, the market is segmented into topical / ophthalmic and surgical. Based on end user, the market is segmented into hospitals, specialty clinics and ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Neurotrophic Keratitis Treatment Market
The growing recognition among clinicians regarding the symptoms and treatment options for neurotrophic keratitis is significantly influencing the market, leading to more timely diagnoses and referrals to specialized care. This increased awareness not only promotes the adoption of innovative therapies but also broadens the scope of patients who can benefit from intervention, thus enhancing physicians' confidence in recommending new treatments. Consequently, there is a heightened demand for approved products, prompting manufacturers to focus on educational initiatives and market outreach. This ongoing engagement in clinical practices fosters improved patient access and outcomes across various healthcare environments globally, driving the overall growth of the Neurotrophic Keratitis Treatment market.
Restraints in the Global Neurotrophic Keratitis Treatment Market
The high costs involved in the development and production of new therapies for neurotrophic keratitis result in elevated retail prices, which many healthcare systems struggle to reimburse. These significant financial barriers restrict patient access, particularly in areas with limited insurance options or inadequate public funding. As a result, healthcare providers may be reluctant to recommend more expensive treatments, instead opting for less costly alternatives or supportive care measures. This financial strain diminishes market demand, hinders widespread acceptance, and can impede the timely introduction of innovative therapies, ultimately stunting overall growth within the global ophthalmic market.
Market Trends of the Global Neurotrophic Keratitis Treatment Market
The Global Neurotrophic Keratitis Treatment market is experiencing significant growth driven by the emergence of integrated diagnostic platforms that combine advanced imaging, biomarker profiling, and artificial intelligence analytics. This innovative convergence enhances clinical capabilities in identifying and monitoring neurotrophic keratitis, facilitating more accurate assessments of corneal nerve density and tear-film dynamics. By allowing for earlier interventions and tailored treatment options, these platforms improve patient adherence and reduce the need for invasive procedures. Additionally, this trend fosters collaboration between ophthalmologists and technology providers, leading to new revenue opportunities for diagnostic equipment manufacturers and reinforcing the market's momentum.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Neurotrophic Keratitis Treatment Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops
- Topical Antibiotics
- Amniotic Membrane Transplantation
- Keratoplasty
- Tarsorrhaphy
- Therapeutic Contact Lenses
Global Neurotrophic Keratitis Treatment Market Size by Disease Stage & CAGR (2026-2033)
- Market Overview
- Stage I
- Stage II
- Stage III
Global Neurotrophic Keratitis Treatment Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Topical / Ophthalmic
- Surgical
Global Neurotrophic Keratitis Treatment Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
Global Neurotrophic Keratitis Treatment Market Size & CAGR (2026-2033)
- North America (Treatment Type, Disease Stage, Route of Administration, End User)
- US
- Canada
- Europe (Treatment Type, Disease Stage, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Disease Stage, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Disease Stage, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Disease Stage, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Dompe farmaceutici S.p.A. (Oxervate)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alcon Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch & Lomb Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (Allergan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Vision
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Santen Pharmaceutical Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Rohto Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ocular Therapeutix Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Leadiant Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ReGenTree LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Neuroptika Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Laboratoires Thea SAS
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zhejiang Conba Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CooperVision Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurolab
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grand Pharma Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
